Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more
Inhalerx Ltd (IRX) - Total Liabilities
Latest total liabilities as of June 2025: AU$2.31 Million AUD
Based on the latest financial reports, Inhalerx Ltd (IRX) has total liabilities worth AU$2.31 Million AUD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Inhalerx Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Inhalerx Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Inhalerx Ltd Competitors by Total Liabilities
The table below lists competitors of Inhalerx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Khind Holdings Bhd
KLSE:7062
|
Malaysia | RM167.60 Million |
|
Winchester Energy Ltd
AU:WEL
|
Australia | AU$1.14 Million |
|
Key Alliance Group Bhd
KLSE:0036
|
Malaysia | RM19.63 Million |
|
Serrano Resources Ltd
PINK:MIRXF
|
USA | $490.03K |
|
Glory Forever PCL
BK:GLORY
|
Thailand | ฿29.16 Million |
|
Norstar
TA:NSTR
|
Israel | ILA25.36 Billion |
|
Argent Minerals Limited
PINK:ARDNF
|
USA | $408.91K |
|
Cahaya Bintang Medan Tbk Pt
JK:CBMF
|
Indonesia | Rp117.80 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Inhalerx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inhalerx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inhalerx Ltd (2016–2024)
The table below shows the annual total liabilities of Inhalerx Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$776.37K | -14.82% |
| 2023-12-31 | AU$911.41K | +156.51% |
| 2022-12-31 | AU$355.32K | +40.25% |
| 2021-12-31 | AU$253.34K | -56.33% |
| 2020-12-31 | AU$580.10K | +104.53% |
| 2019-12-31 | AU$283.63K | -30.54% |
| 2018-12-31 | AU$408.33K | -29.54% |
| 2017-12-31 | AU$579.51K | -53.54% |
| 2016-12-31 | AU$1.25 Million | -- |